Journal
CANCER CELL
Volume 23, Issue 3, Pages 277-286Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2013.02.013
Keywords
-
Categories
Funding
- European Research Council (ERC)
- National Centres of Competence in Research
- Anna Fuller Fund
- Cancer Research UK
- Cancer Research UK [13028] Funding Source: researchfish
Ask authors/readers for more resources
Tumor-associated macrophages (TAMs) promote key processes in tumor progression, like angiogenesis, immunosuppression, invasion, and metastasis. Increasing studies have also shown that TAMs can either enhance or antagonize the antitumor efficacy of cytotoxic chemotherapy, cancer-cell targeting antibodies, and immunotherapeutic agents depending on the type of treatment and tumor model. TAMs also drive reparative mechanisms in tumors after radiotherapy or treatment with vascular-targeting agents. Here, we discuss the biological significance and clinical implications of these findings, with an emphasis on novel approaches that effectively target TAMs to increase the efficacy of such therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available